Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol, vol.27, pp.4733-4773, 2009. ,
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, J Clin Oncol, vol.27, pp.740-745, 2009. ,
Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial, J Clin Oncol, vol.33, pp.2735-2779, 2015. ,
Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy, Clin Cancer Res, vol.20, pp.3550-3559, 2014. ,
Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response, Clin Cancer Res, vol.22, pp.5765-71, 2016. ,
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial, Lancet Oncol, vol.15, pp.943-53, 2014. ,
AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma, Neuro Oncol, vol.18, pp.1304-1316, 2016. ,
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma, N Engl J Med, vol.370, pp.709-731, 2014. ,
A randomized trial of bevacizumab for newly diagnosed glioblastoma, N Engl J Med, vol.370, pp.699-708, 2014. ,
Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial, J Clin Oncol, vol.34, pp.1611-1620, 2016. ,
Phase II part of EORTC study 26101: the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma, J Clin Oncol, vol.34, 2016. ,
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, vol.352, pp.987-96, 2005. ,
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial, Biometrics, vol.31, pp.103-118, 1975. ,
On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial, Biometrics, vol.32, pp.691-695, 1976. ,
Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria, J Clin Oncol, vol.28, pp.222-231, 2010. ,
Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial, Neuro Oncol, vol.16, pp.1630-1638, 2014. ,
MGMT methylation analysis of glioblastoma on the Infinium methylation Bead-Chip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status, Acta Neuropathol, vol.124, pp.547-60, 2012. ,
An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing healthrelated quality of life and symptoms in brain cancer patients, Eur J Cancer, vol.46, pp.1033-1073, 2010. ,
Quality of life assessment in clinical trialsguidelines and a checklist for protocol writers: the U.K. Medical Research Council experience, Eur J Cancer, vol.33, pp.20-28, 1997. ,
Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials -does HRQOL evaluation in prostate cancer research inform clinical decision making?, J Clin Oncol, vol.21, pp.3502-3513, 2003. ,
Construct and concurrent validity of the Hopkins Verbal Learning Test-Revised, Clin Neuropsychol, vol.13, issue.23, pp.348-58, 1995. ,
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials, Iowa City: AJA Associates, vol.25, pp.1188-98, 1989. ,
The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial, 27. Wick W, Weller M, van den Bent M, et al. MGMT testing -the challenges for biomarker-based glioma treatment, vol.51, pp.372-85, 2014. ,